171 related articles for article (PubMed ID: 37958569)
1. Tyrosine Metabolism Pathway Is Downregulated in Dopaminergic Neurons with LRRK2 Overexpression in
Cheng J; Wu BT; Liu HP; Lin WY
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958569
[TBL] [Abstract][Full Text] [Related]
2. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
[TBL] [Abstract][Full Text] [Related]
3. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
[TBL] [Abstract][Full Text] [Related]
5. Dopamine neuron-specific LRRK2 G2019S effects on gene expression revealed by translatome profiling.
Pallos J; Jeng S; McWeeney S; Martin I
Neurobiol Dis; 2021 Jul; 155():105390. PubMed ID: 33984508
[TBL] [Abstract][Full Text] [Related]
6. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
[TBL] [Abstract][Full Text] [Related]
7. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
[TBL] [Abstract][Full Text] [Related]
9. Multiple Pathways of LRRK2-G2019S/Rab10 Interaction in Dopaminergic Neurons.
Fellgett A; Middleton CA; Munns J; Ugbode C; Jaciuch D; Wilson LG; Chawla S; Elliott CJH
J Parkinsons Dis; 2021; 11(4):1805-1820. PubMed ID: 34250948
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
11.
Petridi S; Middleton CA; Ugbode C; Fellgett A; Covill L; Elliott CJH
G3 (Bethesda); 2020 Jun; 10(6):1903-1914. PubMed ID: 32321836
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
[TBL] [Abstract][Full Text] [Related]
13. Cell-autonomous role of leucine-rich repeat kinase in the protection of dopaminergic neuron survival.
Kang J; Huang G; Ma L; Tong Y; Shahapal A; Chen P; Shen J
Elife; 2024 Jun; 12():. PubMed ID: 38856715
[TBL] [Abstract][Full Text] [Related]
14. The APP intracellular domain promotes
Zhang ZW; Tu H; Jiang M; Vanan S; Chia SY; Jang SE; Saw WT; Ong ZW; Ma DR; Zhou ZD; Xu J; Guo KH; Yu WP; Ling SC; Margolin RA; Chain DG; Zeng L; Tan EK
Sci Signal; 2022 Aug; 15(748):eabk3411. PubMed ID: 35998231
[TBL] [Abstract][Full Text] [Related]
15. Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
Lin CH; Lin HI; Chen ML; Lai TT; Cao LP; Farrer MJ; Wu RM; Chien CT
Hum Mol Genet; 2016 May; 25(10):1965-1978. PubMed ID: 26931464
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial Calcium Dysregulation Contributes to Dendrite Degeneration Mediated by PD/LBD-Associated LRRK2 Mutants.
Verma M; Callio J; Otero PA; Sekler I; Wills ZP; Chu CT
J Neurosci; 2017 Nov; 37(46):11151-11165. PubMed ID: 29038245
[TBL] [Abstract][Full Text] [Related]
17. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease.
Calamini B; Geyer N; Huss-Braun N; Bernhardt A; Harsany V; Rival P; Cindhuchao M; Hoffmann D; Gratzer S
Dis Model Mech; 2021 Jun; 14(6):. PubMed ID: 34114604
[TBL] [Abstract][Full Text] [Related]
18. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.
Islam MS; Nolte H; Jacob W; Ziegler AB; Pütz S; Grosjean Y; Szczepanowska K; Trifunovic A; Braun T; Heumann H; Heumann R; Hovemann B; Moore DJ; Krüger M
Hum Mol Genet; 2016 Dec; 25(24):5365-5382. PubMed ID: 27794539
[TBL] [Abstract][Full Text] [Related]
19. The Drosophila hep pathway mediates Lrrk2-induced neurodegeneration.
Yang D; Thomas JM; Li T; Lee Y; Liu Z; Smith WW
Biochem Cell Biol; 2018 Aug; 96(4):441-449. PubMed ID: 29268033
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
